Evidence map›Paper›PMID 42169206›Full record

SynthesisSystematic reviews2026

Impact of the COVID-19 pandemic on diagnosis, and healthcare utilization, among patients with cancer (lung, breast, and pancreas) and cardiovascular diseases (HF, AF, hypertensive, and chronic ischemic heart disease) in Germany: two systematic reviews.

Janine Ropeter, Nina Overhageböck, Maren Dreier, Dörthe Meyerdierks, Adil Imran, Torben Heinsohn, Maren Steinmann, Alexander Kuhlmann, Beate Jahn, Berit Lange and 2 more

Abstract readSystematic Review
In one paragraph

Synthesis in Systematic reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Janine Ropeter *Helmholtz Centre for Infection Research, Department of Epidemiology, Brunswick, Germany.
Nina Overhageböck *Helmholtz Centre for Infection Research, Department of Epidemiology, Brunswick, Germany.
Maren DreierHannover Medical School, Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover, Germany.
Dörthe MeyerdierksHelmholtz Centre for Infection Research, Department of Epidemiology, Brunswick, Germany.
Adil ImranHelmholtz Centre for Infection Research, Department of Epidemiology, Brunswick, Germany.
Torben HeinsohnHelmholtz Centre for Infection Research, Department of Epidemiology, Brunswick, Germany.
Maren SteinmannSchool of Public Health, Department of Health Economics and Health Care Management, Bielefeld University, Bielefeld, Germany.
Alexander KuhlmannFaculty of Medicine, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Beate JahnInstitute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT TIROL-University for Health Sciences and Technology, Hall I. T, Austria.
Berit LangeHelmholtz Centre for Infection Research, Department of Epidemiology, Brunswick, Germany.
Carolina J Klett-Tammen *Helmholtz Centre for Infection Research, Department of Epidemiology, Brunswick, Germany.
Manuela Harries *Helmholtz Centre for Infection Research, Department of Epidemiology, Brunswick, Germany. manuela.harries@helmholtz-hzi.de.ORCID 0000-0001-5238-0103

Funding

Bundesministerium für Forschung, Technologie und Raumfahrt 031L0299H
6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic and related non-pharmaceutical interventions (NPIs) (e.g., lockdowns and contact restrictions) disrupted routine healthcare delivery. In Germany, these measures affected diagnostic and treatment services for people with cancer and cardiovascular diseases, potentially delaying diagnosis and adversely influencing outcomes. We assessed whether and to what extent diagnosis, health utilization and health outcome among patients with selected cancer and cardiovascular conditions changed in Germany during the pandemic.

methodsWe conducted two systematic reviews of studies from Germany on selected cancers (breast, lung and pancreatic) and cardiovascular conditions (atrial fibrillation/flutter, heart failure, hypertensive and chronic ischemic heart disease). Protocols were registered in PROSPERO and the reviews were reported in accordance with PRISMA. We searched PubMed, Web of Science, Cochrane Library, Scopus, and Embase and screened grey literature. Outcomes included changes in new diagnoses, healthcare utilization, treatment, and disease-specific mortality during the pandemic (2020-2023) compared with the pre-pandemic period (2018-2019). Two reviewers independently screened records, extracted data, and assessed risk of bias using an adapted ROBINS-E tool. Owing to heterogeneity, we synthesized findings narratively.

resultsWe screened 1991 records for cancer and 4,981 records for cardiovascular diseases, and included 9 cancer studies and 10 cardiovascular studies. For cancer, several studies reported a relative reduction in new breast and lung cancer diagnoses of up to 25% during lockdown periods; hospital admissions decreased by up to 9%. For cardiovascular conditions, hospital admissions for atrial fibrillation/flutter and heart failure decreased by up to 20%, particularly during pandemic peaks. Evidence on treatment delays, changes in treatment, and mortality was limited, and outcomes for other included diagnoses were often not reported. DISCUSSION: The available evidence indicates substantial reductions in hospital admissions and new diagnoses among patients with cancer and cardiovascular disease in Germany during the pandemic, suggesting major disruptions to care delivery. However, heterogeneity and gaps in the evidence base limit a comprehensive assessment of downstream outcomes. More comprehensive, linked data and further research are needed to quantify the full pandemic's impact and to strengthen health-system resilience for future crises.

Indexed as

Cardiovascular DiseasesCOVID-19NeoplasmsPatient Acceptance of Health CareFemaleGermanyHospitalizationHumansPandemicsCancerCardiovascular diseasesCOVID-19GermanyHealthcare utilizationSystematic review

Identifiers

PMID42169206
PMCPMC13196194

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.